← All trials
NCT06194864
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 18, 2024
- Primary completion
- May 14, 2024
- Completion date
- May 22, 2024
- First posted
- Jan 8, 2024
- Last posted
- Sep 19, 2024
- Enrollment
- 45
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Emalex BiosciencesLead sponsor
- Emalex BiosciencesOfficial
- Syneos HealthCollaborator
- Cambridge Cognition LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.